Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

Clinical Trial ID NCT02369874

Rank	Title	Journal	Year	PubWeight™‹?›
1	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nat Rev Clin Oncol	2015	1.54
2	Immunology and Immunotherapy of Head and Neck Cancer.	J Clin Oncol	2015	1.10
3	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.	J Clin Invest	2015	0.98
4	The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications.	Ann Transl Med	2016	0.93
5	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications.	Front Immunol	2015	0.92
6	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches.	Cancers (Basel)	2015	0.90
7	PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.	Sci Rep	2016	0.80
8	Current clinical immunotherapeutic approaches for head and neck cancer.	F1000Res	2016	0.75